- Home
- INKT vs IGC Comparison
INKT vs IGC Comparison
Compare INKT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- IGC
- Stock Information
- Founded
- INKT 2017
- IGC 2005
- Country
- INKT United States
- IGC United States
- Employees
- INKT N/A
- IGC N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- IGC Health Care
- Exchange
- INKT Nasdaq
- IGC Nasdaq
- Market Cap
- INKT 69.2M
- IGC 39.8M
- IPO Year
- INKT 2021
- IGC N/A
- Fundamental
- Price
- INKT $14.12
- IGC $0.42
- Analyst Decision
- INKT Buy
- IGC Strong Buy
- Analyst Count
- INKT 3
- IGC 2
- Target Price
- INKT $37.50
- IGC $4.00
- AVG Volume (30 Days)
- INKT 47.0K
- IGC 1.4M
- Earning Date
- INKT 11-13-2025
- IGC 11-11-2025
- Dividend Yield
- INKT N/A
- IGC N/A
- EPS Growth
- INKT N/A
- IGC N/A
- EPS
- INKT N/A
- IGC N/A
- Revenue
- INKT N/A
- IGC $1,327,000.00
- Revenue This Year
- INKT N/A
- IGC $15.26
- Revenue Next Year
- INKT N/A
- IGC $3.41
- P/E Ratio
- INKT N/A
- IGC N/A
- Revenue Growth
- INKT N/A
- IGC 24.95
- 52 Week Low
- INKT $4.56
- IGC $0.25
- 52 Week High
- INKT $76.00
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- INKT 46.56
- IGC 55.78
- Support Level
- INKT $14.00
- IGC $0.38
- Resistance Level
- INKT $16.20
- IGC $0.43
- Average True Range (ATR)
- INKT 1.10
- IGC 0.04
- MACD
- INKT -0.01
- IGC -0.00
- Stochastic Oscillator
- INKT 31.62
- IGC 33.33
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.